Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non–small-cell Lung Cancer
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 20 (2) , e208-e217
Abstract
No abstract availableKeywords
Funding Information
- NCI (5P30CA124435)
- NIH
- NCRR
This publication has 33 references indexed in Scilit:
- Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialThe Lancet Oncology, 2016
- Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomasCancer, 2015
- BRAF-mutations in non-small cell lung cancerLung Cancer, 2014
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for ProgressionJNCI: Journal of the National Cancer Institute, 2012
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- The Histopathology of BRAF-V600E–mutated Lung AdenocarcinomaAmerican Journal of Surgical Pathology, 2008
- Mutations of the BRAF gene in human cancerNature, 2002